| Original language | English |
|---|---|
| Pages (from-to) | 793-794 |
| Number of pages | 2 |
| Journal | JACC: Cardiovascular Interventions |
| Volume | 15 |
| Issue number | 7 |
| DOIs | |
| State | Published - 11 Apr 2022 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JACC: Cardiovascular Interventions, Vol. 15, No. 7, 11.04.2022, p. 793-794.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Reply
T2 - Influence of Target Vessel on Post-PCI iFR
AU - Patel, Manesh R.
AU - Jeremias, Allen
AU - Maehara, Akiko
AU - Stone, Gregg W.
N1 - Funding Information: Dr Patel has received research grants from Bayer, Janssen, Amgen, Novartis, the National Heart, Lung, and Blood Institute, Phillips, and HeartFlow; and is an advisory board member for Bayer, Janssen, and HeartFlow. Dr Jeremias has received institutional funding (unrestricted education grant) from Philips/Volcano; and is a consultant for Philips/Volcano, Abbott Vascular, Acist Medical, and Boston Scientific. Dr Maehara is a consultant for Boston Scientific, Philips, and Shockwave. Dr Stone has received speaker honoraria from Pulnovo and Infraredx; is a consultant to Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Vascular Dynamics, Shockwave, V-Wave, Cardiomech, Gore, and Amgen; holds equity and options in Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and Xenter; has received research support to his employer (Mount Sinai Hospital) from Abbott, Bioventrix, Cardiovascular Systems, Phillips, Biosense Webster, Shockwave, Vascular Dynamics, and V-wave; and has a family member (daughter) who is an employee of Medtronic. Funding Information: Dr Patel has received research grants from Bayer, Janssen, Amgen, Novartis, the National Heart, Lung, and Blood Institute, Phillips, and HeartFlow; and is an advisory board member for Bayer, Janssen, and HeartFlow. Dr Jeremias has received institutional funding (unrestricted education grant) from Philips/Volcano; and is a consultant for Philips/Volcano, Abbott Vascular, Acist Medical, and Boston Scientific. Dr Maehara is a consultant for Boston Scientific, Philips, and Shockwave. Dr Stone has received speaker honoraria from Pulnovo and Infraredx; is a consultant to Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Vascular Dynamics, Shockwave, V-Wave, Cardiomech, Gore, and Amgen; holds equity and options in Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and Xenter; has received research support to his employer (Mount Sinai Hospital) from Abbott, Bioventrix, Cardiovascular Systems, Phillips, Biosense Webster, Shockwave, Vascular Dynamics, and V-wave; and has a family member (daughter) who is an employee of Medtronic.
PY - 2022/4/11
Y1 - 2022/4/11
UR - http://www.scopus.com/inward/record.url?scp=85127025581&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2022.02.040
DO - 10.1016/j.jcin.2022.02.040
M3 - Letter
AN - SCOPUS:85127025581
SN - 1936-8798
VL - 15
SP - 793
EP - 794
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 7
ER -